Baltimore, MD, United States of America

Lisa H Conti


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Lisa H Conti: Advancements in Neuroprotection

Introduction: Lisa H Conti is a distinguished inventor based in Baltimore, MD, known for her remarkable contributions to the pharmaceutical field. With one patent to her name, she has demonstrated an innovative approach to addressing neurodegeneration and anxiety. Her work at Nova Pharmaceutical Corporation highlights her commitment to developing effective treatments for central nervous system injuries.

Latest Patents: Lisa H Conti's patent focuses on "Antagonists of specific excitatory amino acid receptors." This invention provides a method and pharmaceutical compositions designed to treat, prevent, or reduce neurodegeneration associated with chronic central nervous system injuries, as well as hypoxic, ischemic, and hypoglycemic conditions. The innovative use of 2-amino-.omega.-phosphonoalkanoic acids with a cycloalkyl group offers an exciting pathway for neuroprotectants and anxiolytics.

Career Highlights: Throughout her career at Nova Pharmaceutical Corporation, Lisa has exemplified dedication and expertise in the field of neuroscience. Her work emphasizes the importance of finding new therapeutic strategies that support patients suffering from various central nervous system disorders. The development of her patented invention showcases her innovative spirit and profound understanding of pharmacology.

Collaborations: Lisa has worked alongside talented colleagues such as Waclaw J Rzeszotarski and Maria E Guzewska. These collaborations have enriched her research endeavors, providing diverse insights and fostering a creative environment essential for groundbreaking discoveries.

Conclusion: Lisa H Conti stands as a testament to the power of innovation in the pharmaceutical industry. Her groundbreaking patent and collaborative efforts reflect her significant impact on neuroprotective therapies. As she continues her work at Nova Pharmaceutical Corporation, the future looks promising for advancements in treatments for central nervous system injuries and anxiety disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…